Navigation Links
Celsion Corporation Provides Business Update
Date:4/23/2013

LAWRENCEVILLE, N.J., April 23, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today is providing a business update, including the latest findings from its analysis of clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  Celsion is evaluating ThermoDox® in a Phase III clinical trial for primary liver cancer (the HEAT Study), a Phase II clinical trial for colorectal liver metastasis and a Phase II clinical trial for recurrent chest wall breast cancer.

Phase III HEAT Study Data Analysis 

The Company has conducted a comprehensive analysis of the data from the Phase III HEAT Study with key principal investigators, data experts and liver cancer experts.  This follows the announcement on January 31, 2013, that ThermoDox® in combination with radiofrequency ablation (RFA) did not meet the study's primary endpoint.  Emerging data from the HEAT Study post analysis demonstrates that ThermoDox® markedly improves progression free survival (PFS) and overall survival (OS) in patients who had optimal RFA.  The analysis indicates that if patients' lesions undergo RFA for 45 minutes or more, they clearly benefitted from ThermoDox®.  These findings apply to HCC lesions from both size cohorts of the HEAT Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of patients.  This data is subject to further verification and review by the HEAT Study Steering Committee. 

"We have completed a thorough review of the HEAT Study and there is clear evidence that ThermoDox® can benefit patients when RFA is optimized," said Dr. Nicholas Borys , Celsion's Vice President and Chief Medical Officer.  "These data are very exciting and consistent with the mechanism of ThermoDox&
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Celsion Corporation Announces $15 Million Registered Direct Offering
2. Todays Research on Celsion, Zogenix, Actavis, and Avanir Pharma
3. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
4. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
5. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
6. Neogen Corporation Announces 2nd Quarter Results Conference Call
7. Luminex Corporation to Present at JP Morgan Healthcare Conference
8. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
9. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
10. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
11. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014  Discovery Laboratories, Inc. ... advancing a new standard of respiratory critical care, will ... August 5, 2014 before the open of the ... will host a live teleconference and webcast at ... conference call, Discovery Labs, management will discuss the ...
(Date:7/29/2014)... , July 29, 2014  ImmunoClin Corporation ... personalized medicine, treatment of infectious diseases as well ... prognosis and prevention of pathologies like cardiovascular disease, ... 1, 2014, ImmunoClin Corporation will complete the strategic ... Washington, D.C. , a key center of ...
(Date:7/29/2014)... Genera Energy Inc. , ... and supply chain advancements, has announced the deployment ... Grange™ and Supply ASSURE™. Both systems were ... aimed at consolidating and simplifying the entire process, ... and feedstock end users. , “Through the Energy ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
Breaking Biology Technology:Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13
... and minerals. Image courtesy of Brain Twist ... an aid to holding off the cold and flu is ... York-based Brain Twist Inc. is launching Defense Vitamin ... boosting beverage utilizing the FreshCan technology of Degussa FreshTech ...
... Circuit (CAFC) issued a patent-law decision last month that inevitably ... will raise the bar for proving gene and protein related ... fragment sequences were useful. Most notably whether the gene fragments ... patent law. , ,The CAFC ruled against the patent applicants ...
... is bombarded with more than 3,000 advertisements each day. So ... most relevant ones. , ,Marketers used to view advertising ... meant blasting the same ad across mass media as often ... huge audience several times. , ,Jay Townley, president of ...
Cached Biology Technology:Court bars patent protection for certain gene fragments 2Court bars patent protection for certain gene fragments 3Court bars patent protection for certain gene fragments 4Turning ads into sales: Context is king 2Turning ads into sales: Context is king 3Turning ads into sales: Context is king 4
(Date:7/29/2014)... major role in locomotion. Swimming microorganisms, such as bacteria ... compared to the viscous forces exerted by the surrounding ... challenge. Now, scientists have found that the direction of ... that induced by a viscoelastic fluid. These findings have ... Nadal from the Alternative Energies and Atomic Energy Commission ...
(Date:7/29/2014)... But on the remote UK overseas territory of Ascension ... is undergoing something of a renaissance. , Writing in ... the University of Exeter and Ascension Island Government Conservation ... at the remote South Atlantic outpost has increased by ... the 1970s. As many as 24,000 nests are now ...
(Date:7/29/2014)... method to create DNAprotein conjugates. The method can ... , DNA linked to proteins including antibodies ... used in diagnostic techniques, nanotechnology and other disciplines. ... can be used for purposes such as ... The method also provides easier access to handling ...
Breaking Biology News(10 mins):Optimum inertial self-propulsion design for snowman-like nanorobot 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2New method provides researchers with efficient tool for tagging proteins 2
... at The Wistar Institute announce the release of an ... along a DNA strand that tell a cell,s transcription ... a particular protein. The Mammalian Promoter Database (MPromDb) ... publicly available data on human and mouse genomics. MPromDb ...
... Carnegie Mellon University,s Manojkumar Puthenveedu has discovered the mechanism ... understanding signaling receptor function. Writing in the journal Cell, ... signaling receptor travels back to the cell membrane after ... live on the cell membrane waiting to be matched ...
... Spanish . , The AZTI-Tecnalia technological centre, in ... dairy product companies within the FUTURAL project, has verified that, ... of a number of dairy products, high pressure technology is ... Tecnolat, the results, especially with ready-to-eat fruit products and in ...
Cached Biology News:New annotated database sifts through mountains of sequencing data to find gene promoters 2New annotated database sifts through mountains of sequencing data to find gene promoters 3Carnegie Mellon researchers discover mechanism for signaling receptor recycling 2Carnegie Mellon researchers discover mechanism for signaling receptor recycling 3Research shows positive results with high pressure technology for certain dairy products 2
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
GBL Antibody...
...
... Sequencing Quality 96 Well ... BAC template preparation from 1.5ml ... suitable for automated fluorescent sequencing ... DNA; Utilizes ProPrep strategy which ...
Biology Products: